- Home
- TXMD vs NEA Comparison
TXMD vs NEA Comparison
Compare TXMD & NEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- NEA
- Stock Information
- Founded
- TXMD 2008
- NEA 2002
- Country
- TXMD United States
- NEA United States
- Employees
- TXMD N/A
- NEA N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- NEA Finance/Investors Services
- Sector
- TXMD Health Care
- NEA Finance
- Exchange
- TXMD Nasdaq
- NEA Nasdaq
- Market Cap
- TXMD 12.7M
- NEA 3.4B
- IPO Year
- TXMD N/A
- NEA N/A
- Fundamental
- Price
- TXMD $1.06
- NEA $11.32
- Analyst Decision
- TXMD
- NEA
- Analyst Count
- TXMD 0
- NEA 0
- Target Price
- TXMD N/A
- NEA N/A
- AVG Volume (30 Days)
- TXMD 17.5K
- NEA 803.4K
- Earning Date
- TXMD 11-11-2025
- NEA 01-01-0001
- Dividend Yield
- TXMD N/A
- NEA 4.23%
- EPS Growth
- TXMD N/A
- NEA N/A
- EPS
- TXMD N/A
- NEA N/A
- Revenue
- TXMD $2,559,000.00
- NEA N/A
- Revenue This Year
- TXMD $427.09
- NEA N/A
- Revenue Next Year
- TXMD N/A
- NEA N/A
- P/E Ratio
- TXMD N/A
- NEA N/A
- Revenue Growth
- TXMD 156.93
- NEA N/A
- 52 Week Low
- TXMD $0.70
- NEA $9.20
- 52 Week High
- TXMD $2.44
- NEA $11.37
- Technical
- Relative Strength Index (RSI)
- TXMD 40.43
- NEA 64.38
- Support Level
- TXMD $1.06
- NEA $10.92
- Resistance Level
- TXMD $1.14
- NEA $11.46
- Average True Range (ATR)
- TXMD 0.05
- NEA 0.08
- MACD
- TXMD -0.00
- NEA 0.02
- Stochastic Oscillator
- TXMD 5.26
- NEA 74.07
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About NEA Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities. The company invest in Transportation, Utilities, Healthcare, Education and Civics, and other sectors, with maximum investment in Transportation.